Pharmaceutical HIV specialist company ViiV Healthcare, which is majority owned by GlaxoSmithKline, today announced the authorization of Vocabria (cabotegravir injection and tablets) in combination with Janssen’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed. 21 December 2020